JOHN HOPE FRANKLIN CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1838-01-01

Employees: 5K

Market Cap: -

Website: http://www.duke.edu

Clinical Trials

STARBRITE: A Randomized Pilot Trial of BNP-Guided Therapy in Patients With Advanced Heart Failure

Phase 2

Completed

Conditions: Congestive Heart Failure

Interventions: Other: clinical assessment
Device: Brain Natriuretic Peptide Levels -- Diagnostic testing

First Posted Date: 2007-06-11

Last Posted Date: 2023-11-15

Lead Sponsor: Duke University

Target Recruit Count: 135

Registration Number: NCT00484770

Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction

Not Applicable

Withdrawn

Conditions: Kidney Diseases

Interventions: Drug: fondaparinux

First Posted Date: 2007-06-07

Last Posted Date: 2014-07-29

Lead Sponsor: Duke University

Registration Number: NCT00483600

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

Recruiting

Conditions: Antiphospholipid Syndrome

First Posted Date: 2007-06-05

Last Posted Date: 2025-03-19

Lead Sponsor: Duke University

Target Recruit Count: 2800

Registration Number: NCT00482794

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Abraxane
Drug: Bevacizumab
Drug: Carboplatin

First Posted Date: 2007-05-28

Last Posted Date: 2015-02-18

Lead Sponsor: Duke University

Target Recruit Count: 41

Registration Number: NCT00479674

Locations: 🇺🇸
Presbyterian Health Care, Charlotte, North Carolina, United States
🇺🇸
Northeast Oncology Associates, Concord, North Carolina, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Vinorelbine Tartrate
Drug: Gemcitabine
Drug: Bevacizumab
Drug: CPT-11
Drug: Paclitaxel

First Posted Date: 2007-05-22

Last Posted Date: 2013-07-17

Lead Sponsor: Duke University

Target Recruit Count: 16

Registration Number: NCT00476827

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Palm Beach Cancer Center Institute, West Palm Beach, Florida, United States
🇺🇸
Presbyterian Health Care, Charlotte, North Carolina, United States

and more 1 locations

The Treatment of Insomnia in Patients With HIV Disease

Phase 4

Completed

Conditions: HIV Infections
Insomnia

Interventions: Drug: Placebo
Drug: Doxepin
Drug: Temazepam

First Posted Date: 2007-04-27

Last Posted Date: 2013-07-30

Lead Sponsor: Duke University

Target Recruit Count: 44

Registration Number: NCT00465972

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Metabolic Signatures and Biomarkers in Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Other: Healthy volunteers
Drug: Aripiprazole
Drug: Risperidone

First Posted Date: 2007-04-27

Last Posted Date: 2014-07-25

Lead Sponsor: Duke University

Target Recruit Count: 71

Registration Number: NCT00466310

Locations: 🇺🇸
John Umstead Hospital, Butner, North Carolina, United States

Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates

Phase 1

Completed

Conditions: Osteonecrosis

Interventions: Device: hyperbaric oxygen
Device: non-treated control group

First Posted Date: 2007-04-18

Last Posted Date: 2013-02-21

Lead Sponsor: Duke University

Target Recruit Count: 54

Registration Number: NCT00462098

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Phase 2

Completed

Conditions: Stomach Neoplasms
Esophageal Neoplasms
Neoplasm Metastasis

Interventions: Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)

First Posted Date: 2007-03-14

Last Posted Date: 2015-02-13

Lead Sponsor: Duke University

Target Recruit Count: 60

Registration Number: NCT00447330

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of Wake Forest Baptist Medical Center, Winston Salem, North Carolina, United States

CALERIE: Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy

Not Applicable

Completed

Conditions: Aging

Interventions: Behavioral: Caloric Restriction (CR)
Behavioral: Control

First Posted Date: 2007-01-26

Last Posted Date: 2022-03-16

Lead Sponsor: Duke University

Target Recruit Count: 238

Registration Number: NCT00427193

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸
Jean Mayer Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy